Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Clinical trial NCT02502708 · COMPLETED

Trial details

NCT number: NCT02502708
Sponsor: NewLink Genetics Corporation
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma Multiforme Glioma Gliosarcoma Malignant Brain Tumor Ependymoma Medulloblastoma Diffuse Intrinsic Pontine Glioma Primary CNS Tumor

Start date: 2015-10-01
Primary completion: 2019-12-12
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.